MarketLens
Sign Up
Investment Ideas

A Game Changer for Schizophrenia Treatment? Teva and Medincell's Olanzapine LAI Accepted by FDA

6 months ago
SHARE THIS ON:

A Game Changer for Schizophrenia Treatment? Teva and Medincell's Olanzapine LAI Accepted by FDA

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

What Does Teva's Recent FDA Acceptance Mean for Investors

What Does Teva's Recent FDA Acceptance Mean for Investors

6 months ago
Is Roche's Fenebrutinib a Game Changer for Multiple Sclerosis Treatment

Is Roche's Fenebrutinib a Game Changer for Multiple Sclerosis Treatment

5 months ago
Is UCB's $2.2 Billion Bet on Candid Therapeutics a Game Changer for Autoimmune Treatment

Is UCB's $2.2 Billion Bet on Candid Therapeutics a Game Changer for Autoimmune Treatment

3 months ago
What Does FDA Orphan Drug Designation Mean for Cure Rare Disease's SCA3 Treatment

What Does FDA Orphan Drug Designation Mean for Cure Rare Disease's SCA3 Treatment

5 months ago

Category

TopFeaturedPro OnlyStock AnalysisInvestment IdeasETFsCrypto

You may also like

Stock News•1 week ago

Definium Therapeutics' DT120 Meets Phase III Goals in GAD Study

Definium Therapeutics' DT120 met its Phase III primary and key secondary endpoints in the Voyage GAD study, showing rapid, durable anxiety improvements through 12 weeks after a single 100 mcg dose.
DFTX
Stock News•2 weeks ago

SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome

NeuroThera Labs launched its Phase IIb trial site at Yale Child Study Center for a first-of-its-kind Tourette syndrome treatment, after SciSparc announced the initiation on Aug. 5, 2026.
SPRC
Stock News•3 weeks ago

Medincell: UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook

UZEDY® Q2 net sales hit a record $77M, up 43% YoY. Teva raised its 2026 revenue outlook to $270M–$290M, from $250M–$280M, citing strong growth.
TEVA
Stock News•1 months ago

TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia

TG Therapeutics launched a Phase 2 trial of BRIUMVI in ~60 treatment-resistant schizophrenia patients, based on emerging evidence linking immune dysfunction to the disease.
TGTX

Breaking News

View All →
Event-Driven Investing
Shareholder Rights

Featured Articles

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

1 week ago
Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

1 week ago
Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

1 week ago

Top Headlines

View More →
Stock News•48 minutes ago

Between Amazon, Alphabet, and Meta, Microsoft is Most Likely to Deliver Best Free Cash Flow in 2026

Stock News•49 minutes ago

Amazon Web Services Backlog Reaches $496 Billion: Does That Make Amazon Stock a No Brainer Buy?

Stock News•1 hour ago

Micron (MU) Falls More Steeply Than Broader Market: What Investors Need to Know

Stock News•1 hour ago

Nvidia's $20 Billion Groq Bet Is Going Live Before the End of 2026. Here's What It Means for Investors.

Stock News•1 hour ago

Q2 Earnings Season Winds Down: 3 Companies That Broke Records